Immunology ( including Transplantation ) and Infectious Diseases W orldwide sales of Prograf have held up due to growth in Japan, Asia & Oceania. In the field of immunology including transplantation,  Astellas is working to sustain its Prograf business on a  global scale. Supported by growth in China and South Korea, sales  increased 32% in Asia & Oceania. Sales of Prograf (including the once-daily formulation  Advagraf/Graceptor/ASTAGRAF XL) rose 12% year on  year in fiscal 2013 to ¥181.4 billion, partly due to the  effect of foreign exchange rates. Local-currency sales  declined in the Americas and EMEA due to generic   competition, but global sales held up as the result of  growth in Japan and Asia & Oceania. Rheumatoid arthritis treatment Cimzia, which was  launched in Japan in March 2013, posted fiscal 2013  sales of ¥3.2 billion. In June 2014, we filed an application  for the approval of an expanded indication that includes  rheumatoid arthritis in patients not previously treated with  anti-rheumatic drugs. In the field of infectious diseases,  sales in fiscal 2013 of Funguard/MYCAMINE rose 18%  compared with the previous year, partly due to foreign  exchange effects. Sales in Japan rose 2.0% due to steady growth in  Graceptor. The growth was partially offset by a fall in sales  after the entry of generic versions of the drug in June  2013. Generic competition also eroded sales in the   Americas, where sales declined 22% year on year on a  U.S. dollar basis. We launched ASTAGRAF XL in the U.S.  in August 2013. In EMEA, while sales of Advagraf contin- ued to grow, price reductions in multiple countries and  generic competition led to a 1.3% decline in euro-based  sales of Prograf via in-house distribution channels.  In terms of the pipeline for new drug candidates to  follow these products, in the field of infectious diseases,  Astellas filed new drug applications in Japan for ASP7374  (seasonal influenza vaccine) in May 2014 and in the U.S.  for isavuconazole (azole antifungal) in July 2014. In the  field of immunology including transplantation, Astellas is  conducting clinical trials on ASP015K (for the treatment of  rheumatoid arthritis) and ASKP1240 (for the prevention of  organ transplant rejection). Review of Operations Sales of Funguard/MYCAMINE by Region  Sales of Prograf by Region (Including Advagraf/Graceptor/ASTAGRAF XL) 0 40 30 20 10 30.7 6.0 9.5 12.9 2.3 36.2 8.8 8.6 10.1 11.7 12.3 3.4 36.1 11.7 10.9 12.3 3.4 36.8 11.4 4.4 2013.3 2014.3 2015.3  (Forecasts) IFRS J-GAAP  Japan   Americas   EMEA   Asia & Oceania (¥ billion) +18% +2% 0 200 150 100 50 161.8 57.5 31.5 49.4 18.9 181.4 71.2 29.6 50.4 25.0 181.1 70.8 29.6 50.4 25.0 181.3 71.4 4.4 5.2 5.2 29.2 27.4 49.6 3.7 IFRS J-GAAP 2013.3 2014.3 2015.3  (Forecasts)  Japan   Americas   EMEA   Asia & Oceania   Export (¥ billion) +12% +0% Annual Report 2014 _  Astellas Pharma Inc.  43